Почетна › Дисфункција леве коморе › Охајо
Kliničke studije za Дисфункција леве коморе u državi Охајо
4 studija za Дисфункција леве коморе traži učesnike na lokacijama u državi Охајо.
Gradovi u državi Охајо
Zvanični tekst studije (na engleskom)
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- Cincinnati Children's Hospital Medical Center ( Site 0034), Cincinnati
- Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022), Cleveland
Тражи се учесникФаза 2/3
29 Days – 17 Years · Оба пола · Ажурирано 13. 11. 2026. · NCT05714085A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension, Cincinnati
- Cleveland Clinic Children's, Cleveland
- Nationwide Children's Hospital - Cardiology, Columbus
Тражи се учесникФаза 3
До 18 година · Оба пола · Ажурирано 27. 10. 2026. · NCT07192952The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- University Hospitals Cleveland Medical Center, Cleveland
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT05427370A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension, Cincinnati
- Cleveland Clinic Children's, Cleveland
- Nationwide Children's Hospital - Cardiology, Columbus
Тражи се учесникФаза 3
6 Months – 17 Years · Оба пола · Ажурирано 15. 10. 2026. · NCT07188805Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.